The effects of fetal and childhood exposure to antiretroviral agents

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE2, 2012, Pages

  Mas, Catherine M ^a   Miller, Tracie L ^a   Cordero, Christina ^a   Dauphin, Danielle ^a   White, Marie Boursiquot ^a   Vila, Christie K ^a   Somarriba, Gabriel ^a   Wilkinson, James D ^a   Lipshultz, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Cardiomyopathy; Highly active antiretroviral therapy; HIV; Mitochondrial dysfunction; Preterm delivery

Indexed keywords

EID: 84879820712     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S2-001     Document Type: Review

References (116)

1. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484-494.
2. Suksomboon N, Poolsup N, Ket-Aim S (2007) Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 32: 293-311.
3. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, et al. (2011) Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIVpositive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 57: 76-85.
4. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, et al. (2008) Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 153: 491-497.
5. Foster C, Lyall H (2008) HIV and mitochondrial toxicity in children. J Antimicrob Chemother 61: 8-12.
6. Walker UA, Setzer B, Venhoff N (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16: 2165-2173.
7. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, et al. (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354: 1084-1089.
8. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, et al. (2007) In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 21: 929-938.
9. Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, et al. (2010) Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. J Infect Dis 202: 291-301.
10. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, et al. (2003) Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 32: 370-374.
11. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, et al. (2003) Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33: 175-183.
12. Walker VE, Poirier MC (2007) Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48: 159-165.
13. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, et al. (2003) Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 17: 1769-1785.
14. Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, et al. (2009) Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics 124: e1189-1197.
15. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, et al. (2000) Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3'-azido-3'-deoxythymidine. AIDS Res Hum Retroviruses 16: 635-644.
16. Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, et al. (2004) Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 20: 91-100.
17. Chan SS, Santos JH, Meyer JN, Mandavilli BS, Cook DL, Jr., et al. (2007) Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 48: 190-200.
18. Walker DM, Poirier MC, Campen MJ, Cook DL, Jr., Divi RL, et al. (2004) Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3'-azido-3'-deoxythymidine. Cardiovasc Toxicol 4: 133-153.
19. Torres SM, March TH, Carter MM, McCash CL, Seilkop SK, et al. (2010) In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue. Cardiovasc Toxicol 10: 37-50.
20. Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR (2004) Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 4: 117-131.
21. Torres SM, Walker DM, McCash CL, Carter MM, Ming J, et al. (2009) Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1. Environ Mol Mutagen 50: 10-26.
22. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, et al. (2005) Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 40: 161-168.
23. Vigano A, Brambilla P, Pattarino G, Stucchi S, Fasan S, et al. (2009) Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 29: 101-109.
24. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, et al. (2005) In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191: 1686-1696.
25. Masia M, Padilla S, Bernal E, Almenar MV, Molina J, et al. (2007) Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 29: 1448-1455.
26. Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, et al. (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 12: 489-500.
27. Ben-Romano R, Rudich A, Etzion S, Potashnik R, Kagan E, et al. (2006) Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 11: 1051-1060.
28. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883.
29. Hruz PW, Yan Q, Struthers H, Jay PY (2008) HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J 22: 2161-2167.
30. Hruz PW, Murata H, Qiu H, Mueckler M (2002) Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51: 937-942.
31. Yan Q, Hruz PW (2005) Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40: 398-403.
32. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, et al. (2002) Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16: F1-8.
33. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, et al. (2005) Insulin sensitivity and beta-cell function in protease inhibitor-treated and-naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 90: 168-174.
34. Murata H, Hruz PW, Mueckler M (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 20251-20254.
35. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-58.
36. Fisher SD, Easley KA, Orav EJ, Colan SD, Kaplan S, et al. (2005) Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J 150: 439-447.
37. Starc TJ, Lipshultz SE, Kaplan S, Easley KA, Bricker JT, et al. (1999) Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Pediatrics 104: e14.
38. Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, et al. (1994) Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 24: 1025-1032.
39. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 14: 1071-1077.
40. Miller TL, Evans SJ, Orav EJ, Morris V, McIntosh K, et al. (1993) Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr 57: 588-592.
41. Lipshultz SE (2010) Association of cardiac structure and function with in utero antiretroviral exposure among uninfected children born to HIV-infected mothers in the pediatric HIV/AIDS cohort study. Circulation 122: A16026.
42. Lipshultz SE (2009) Antiretroviral therapy (ART) cardiac effects in HIV-infected children: the multicenter NHLBI cardiac highly active antiretroviral therapy (CHAART-II) study. Circulation 120: S909.
43. Lavigne JE, Shearer WT, Thompson B, Orav EJ, Starc TJ, et al. (2004) Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. Cardiovasc Toxicol 4: 187-197.
44. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, et al. (2002) Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study. Lancet 360: 368-373.
45. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, et al. (2000) Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 343: 759-766.
46. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, McIntosh K, et al. (1992) Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 327: 1260-1265.
47. Torres SM, Divi RL, Walker DM, McCash CL, Carter MM, et al. (2010) In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue. Cardiovasc Toxicol 10: 87-99.
48. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, et al. (2011) No association of myocardial infarction with ABC use: an FDA Meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, Boston, MA. Abstract 808.
49. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, et al. (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 25: 1289-1298.
50. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P (2011) Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 53: 84-91.
51. Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, et al. (2011) Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide population-based cohort study. AIDS 25:1637-1646.
52. Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, et al. (2006) Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 194: 1089-1097.
53. Feiterna-Sperling C, Weizsaecker K, Buhrer C, Casteleyn S, Loui A, et al. (2007) Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 45: 43-51.
54. Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, et al. (2007) Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 48: 322-329.
55. Lipshultz SE (2009) Increased left ventricular and aortic dimensions in long-term multiagent antiretroviral therapy (ART)-treated HIV-infected children: the NIH multicenter pediatric HIV/AIDS cohort study (PHACS). Circulation 120: S909.
56. Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, et al. (2010) Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J Acquir Immune Defic Syndr 55: 182-188.
57. Mikhail IJ, Purdy JB, Dimock DS, Thomas VM, Muldoon NA, et al. (2011) High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life. Pediatr Infect Dis J 30:710-712.
58. Zareba KM, Lavigne JE, Lipshultz SE (2004) Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol 4: 271-279.
59. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL (2011) Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 57: 245-253.
60. Charakida M, Donald AE, Green H, Storry C, Clapson M, et al. (2005) Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 112: 103-109.
61. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, et al. (1998) Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 97: 1246-1256.
62. Werner ML, Pone MV, Fonseca VM, Chaves CR (2010) Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J Pediatr (Rio J) 86: 27-32.
63. Shikuma CM, Gerschenson M, Chow D, Libutti DE, Willis JH, et al. (2008) Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retroviruses 24: 1255-1262.
64. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, et al. (2008) Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 13: 715-722.
65. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J (2003) Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 17: 2437-2444.
66. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP (2001) Lipodystrophy in HIVinfected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 27: 30-34.
67. McComsey GA, Leonard E (2004) Metabolic complications of HIV therapy in children. AIDS 18: 1753-1768.
68. Geffner M, Jacobson D, Miller T, et al. (2009) Insulin resistance in adolescents with HIV infection. Paper presented at: Pediatric Academic Societies annual meeting; Baltimore, MD.
69. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, et al. (2011) Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive, " a randomized, controlled trial. J Clin Endocrinol Metab 96: 2236-2247.
70. Thorne C, Patel D, Newell ML (2004) Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 18: 2337-2339.
71. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, et al. (2008) Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 9: 6-13.
72. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA (2007) Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 21: 1019-1026.
73. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, et al. (2010) Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 201: 1035-1044.
74. Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, et al. (2011) Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr 56: 131-138.
75. Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, et al. (2001) Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2 C2 human immunodeficiency virus multicenter study. Pediatrics 108: 1287-1296. 76.(2000) Combination antiretroviral therapy and duration of pregnancy. AIDS 14: 2913-2920.
76. Townsend C, Schulte J, Thorne C, Dominguez KI, Tookey PA, et al. (2010) Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 117: 1399-1410.
77. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ (2006) Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 193: 1195-1201.
78. Kowalska A, Niemiec T, El Midaoui A, Burkacka E (2003) Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women. Med Wieku Rozwoj 7: 459-468.
79. Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, et al. (2008) Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 22: 1815-1820.
80. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, et al. (2009) No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 23: 1235-1243.
81. Stagi S, Galli L, Cecchi C, Chiappini E, Losi S, et al. (2010) Final height in patients perinatally infected with the human immunodeficiency virus. Horm Res Paediatr 74: 165-171.
82. Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR, 3rd, et al. (2001) Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 108: E72.
83. Mueller BU, Sleasman J, Nelson RP, Jr., Smith S, Deutsch PJ, et al. (1998) A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 102: 101-109.
84. Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, et al. (2010) Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr 10: 56.
85. Miller TL (2003) Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS 17 Suppl 1: S130-140.
86. Miller TL, Agostoni C, Duggan C, Guarino A, Manary M, et al. (2008) Gastrointestinal and nutritional complications of human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr 47: 247-253.
87. Jacobson DL (2005) Predictors of bone mineral density in human immunodeficiency virus-1 infected children. Journal of pediatric gastroenterology and nutrition 41: 339.
88. Glesby MJ (2003) Bone disorders in human immunodeficiency virus infection. Clin Infect Dis 37 Suppl 2: S91-95.
89. McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, et al. (2001) Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIVseropositive men and women. Am J Clin Nutr 74: 679-686.
90. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, et al. (2002) Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 29: 450-454.
91. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, et al. (2001) Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15: 1823-1829.
92. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
93. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, et al. (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51: 554-561.
94. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23: 817-824.
95. Hendricks KM, Mwamburi DM, Newby PK, Wanke CA (2008) Dietary patterns and health and nutrition outcomes in men living with HIV infection. Am J Clin Nutr 88: 1584-1592.
96. Sharma TS, Kinnamon DD, Duggan C, Weinberg GA, Furuta L, et al. (2008) Changes in macronutrient intake among HIV-infected children between 1995 and 2004. Am J Clin Nutr 88: 384-391.
97. Parakh A, Dubey AP, Kumar A, Maheshwari A (2009) Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr 76: 1017-1021.
98. Rodriguez de la Concepcion ML, Yubero P, Domingo JC, Iglesias R, Domingo P, et al. (2005) Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antivir Ther 10: 515-526.
99. Caron-Debarle M, Boccara F, Lagathu C, Antoine B, Cervera P, et al. (2010) Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des 16: 3352-3360.
100. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815.
101. Lipshultz SE (1995) Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332: 1738-1744.
102. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al. (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23: 2629-2636.
103. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, et al. (2000) Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 102: 1542-1548.
104. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, et al. (2003) A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 187: 725-735.
105. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, et al. (2004) Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351: 217-228.
106. Omer SB (2011) Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 25: 767-776.
107. Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, et al. (2004) Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 114: e598-603.
108. Ekouevi DK, Toure R, Becquet R, Viho I, Sakarovitch C, et al. (2006) Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 118: e1071-1077.
109. Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL (1998) Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 24: 247-250.
110. U.S. State Department. Prevention: Direct FY2010 Prevention of Motherto-Child Transmission Program Results. Annual Report to Congress on the President's Emergency Plan for AIDS Relief.
111. El-Sadr WM, Hoos D (2008) The President's Emergency Plan for AIDS Relief--is the emergency over? N Engl J Med 359: 553-555.
112. Ciaranello AL, Seage GR, 3rd, Freedberg KA, Weinstein MC, Lockman S, et al. (2008) Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS 22: 2359-2369.
113. Wogan GN (2007) Does perinatal antiretroviral therapy create an iatrogenic cancer risk? Environmental and molecular mutagenesis 48: 210-214.
114. Poirier MC, Olivero OA, Walker DM, Walker VE (2004) Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199: 151-161.
115. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010; pp 1-117.
116. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, et al. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11: 950-961.